Clinical trials: PCI Patients
Atrial Fibrillation, Percutaneous Coronary Intervention
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT)…
- Trial name
- PIONEER AF-PCI (NCT01830543)
- Testing
- rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg
- Where
- 348 sites in United States, Argentina and 23 more
- Volunteers
- 2,124 people
- Sponsor
- Janssen Scientific Affairs, LLC
ST Segment Elevation Myocardial Infarction, Percutaneous Coronary Intervention
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI
In STEMI patients undergoing PPCI there is a delayed onset of action of oral P2Y12 receptor inhibitors, including prasugrel and ticagrelor.
- Trial name
- CANTIC (NCT03247738)
- Testing
- Cangrelor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Alpha1-Antitrypsin Deficiency
Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency
This study is a multicenter, open-label trial to evaluate the safety and pharmacokinetics of weekly intravenous infusions of 60 mg/kg of Alpha-1 MP (alpha1-proteinase inhibitor (human), modified process) for 8 weeks.
- Trial name
- NCT02870309
- Testing
- Alpha-1 MP
- Where
- 2 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Grifols Therapeutics LLC
Myocardial Infarction
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community…
- Trial name
- NCT00623623
- Testing
- primary PCI, enoxaparin, catheterisation
- Where
- 201 sites in Austria, Belgium and 14 more
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Graft-Versus-Host Disease (GVHD) Acute on Chronic
Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)
This phase I/II trial evaluates the efficacy and adverse effects of alpha 1 anti-trypsin (AAT) for the treatment of acute graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation.
- Trial name
- NCT01523821
- Testing
- Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Cardiovascular Diseases, Heart Diseases
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also referred to as PCI) in which a doctor will…
- Trial name
- NCT00059215
- Testing
- Prasugrel (CS-747), Clopidogrel
- Where
- 2 sites in United States, Canada
- Volunteers
- 905 people
- Sponsor
- Eli Lilly and Company
Percutaneous Coronary Intervention
Chewed Versus Integral Pill of Ticagrelor
Hypothesis The primary question the investigators propose to answer is whether all patients undergoing percutaneous coronary intervention (PCI) with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug…
- Trial name
- NCT03708588
- Testing
- Ticagrelor
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Wake Forest University Health Sciences
Alpha-1 Antitrypsin Deficiency
Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
Assessment of the safety and efficacy of intramuscular (IM) administration of a recombinant adenoassociated virus (rAAV) alpha-1 antitrypsin (AAT) vector (rAAV1-CB-hAAT) in AAT-deficient adults at three dosage levels [6.0 ×…
- Trial name
- NCT01054339
- Testing
- rAAV1-CB-hAAT
- Where
- 4 sites in United States, Ireland
- Volunteers
- 9 people
- Sponsor
- Beacon Therapeutics
Coronary Disease
Effects of Atorvastatin on Myonecrosis
This study is designed as a prospective, randomized, placebo-controlled, double-blind analysis of atorvastatin 80 mg versus placebo administered on average 4 hours prior to percutaneous coronary intervention [PCI] (at least 2…
- Trial name
- NCT00344019
- Testing
- Atorvastatin 80mg, Screening
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Beth Israel Deaconess Medical Center
Angina
Ranolazine Among Unrevascularized Chronic Stable Angina Patients
This is a prospective, double-blind, placebo-controlled, randomized, single-center (North Florida- South Georgia VA Medical Center) study.
- Trial name
- IMWELL (NCT02265796)
- Testing
- Ranolazine, Sugar pill
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- North Florida Foundation for Research and Education
Acute Coronary Syndrome
MT1002 Phase II Study in ACS Patients With PCI
This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI.
- Trial name
- NCT04723186
- Testing
- MT1002 for Injection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Coronary Artery Disease
Anti-inflammatory Effects of Colchicine in PCI
Peri-procedural inflammation is associated with increased rates of post-procedural myocardial infarction (MI), which occur in up to 35% of PCI patients and are themselves associated with increased risk of later MI and death.
- Trial name
- NCT01709981
- Testing
- Colchicine
- Where
- 3 sites in United States
- Volunteers
- 280 people
- Sponsor
- NYU Langone Health
Angina Pectoris, Angina, Unstable
SPECTACL: SPECTroscopic Assessment of Coronary Lipid
The purpose of this study is to evaluate a near-infrared (NIR) spectroscopy system that has been designed to identify the chemical composition of coronary artery plaques in patients undergoing a percutaneous coronary intervention…
- Conditions
- Angina Pectoris, Angina, Unstable, Myocardial Infarction
- Trial name
- SPECTACL (NCT00330928)
- Testing
- Near Infrared Spectroscopy (NIRS) Imaging, intravascular ultrasound (IVUS)
- Where
- 6 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Infraredx
Bleeding Complications
Clopidogrel Monotherapy in Patients With High Bleeding Risk
The goal of this research is to show that a shorter duration of two antiplatelet medications (compared to the standard of care) is safe and effective while reducing the risk of bleeding complications.
- Trial name
- NCT05223335
- Testing
- Clopidogrel, Prasugrel, Tricagrelor
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Alpha 1-Antitrypsin Deficiency
Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)
The goal of this trial was to explore the utility of evaluating emphysema progression through CT scans measuring lung density during a 2 year period of weekly infusions of either placebo or human alpha-1-antitrypsin (AAT…
- Trial name
- NCT00263887
- Testing
- Alpha1-Proteinase Inhibitor (Human), Albumin (Human) 20%, United States Pharmacopeia (USP)
- Where
- 3 sites in Denmark, Sweden and 1 more
- Volunteers
- 77 people
- Sponsor
- Grifols Therapeutics LLC
Non ST Segment Elevation Acute Coronary Syndrome
Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.
- Trial name
- NCT01962428
- Testing
- ticagrelor
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Heart Catheterization
Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention
To assess whether two doses of dabigatran etexilate (110 mg twice daily (b.i.d) and 150 mg twice daily (b.i.d)) as compared to unfractionated heparin (UFH), both in addition to a standard dual antiplatelet regimen, provide…
- Trial name
- NCT00818753
- Testing
- dabigatran 110 mg, dabigatran 150 mg, unfractionated heparin
- Where
- 4 sites in Netherlands
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Non-ST Elevation Myocardial Infarction
Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.
- Trial name
- NCT03114995
- Testing
- Tirofiban
- Volunteers
- 140 people
- Sponsor
- Seoul National University Bundang Hospital
Heart Attack
P3AMI Antiplatelet Trial
Major heart attacks are caused by a numerous factors, including sudden clot formation in a coronary artery leading to a blockage and heart muscle death. The clots are largely made of sticky clotting blood cells (platelets).
- Trial name
- NCT02376283
- Testing
- Prasugrel, Clopidogrel, ticagrelor
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Anterior Wall Acute Myocardial Infarction
Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)
The primary objective of the study is to collect confirmatory data supporting the safety and effectiveness of SSO2 Therapy in treatment of anterior acute myocardial infarction (AMI) patients who have undergone successful…
- Trial name
- IC-HOT (NCT02603835)
- Testing
- SSO2 Therapy
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- TherOx